In the article by Hegi et al. [16], they conducted seminal work showing that patients with methylated MGMT promoters exhibited significantly better survival outcomes when treated with TMZ compared to those with unmethylated MGMT, who often showed rapid tumor progression and limited response to therapy. Here, MGMT is linked to neoplasm.